Erythropoietin accelerates smooth muscle cell-rich vascular lesion formation in mice through endothelial cell activation involving enhanced PDGF-BB release

Blood

Volumn 115, Issue 7, 2010, Pages 1453-1460

  Janmaat, Maarten L ^a   Heerkens, Jasper L T ^a   De Bruin, Alexander M ^a   Klous, Anita ^a   De Waard, Vivian ^a   De Vries, Carlie J M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; PLATELET DERIVED GROWTH FACTOR BB; RECOMBINANT ERYTHROPOIETIN; STAT5 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ANGIOGENIC FACTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET-DERIVED GROWTH FACTOR BB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY LIGATION; ARTICLE; BLOOD; BLOOD VESSEL; CAROTID ARTERY; CELL ACTIVATION; CELL COUNT; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; ENDOTHELIUM CELL; ERYTHROCYTE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; INTIMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE FIBER; STEM CELL; UMBILICAL VEIN; VASCULAR LESION; ANIMAL; CAROTID ARTERY DISEASE; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; LIGATION; METABOLISM; MOUSE STRAIN; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; UMBILICAL ARTERY; VASCULAR SMOOTH MUSCLE;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; LIGATION; MALE; MICE; MICE, INBRED STRAINS; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; STAT5 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA; TUNICA INTIMA; UMBILICAL ARTERIES; UMBILICAL VEINS;

EID: 77949889342     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-230870     Document Type: Article

References (20)

1. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int. 2006;70(2):246-250. (Pubitemid 44086573)
2. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003;102(4):1340-1346. (Pubitemid 36988041)
3. Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A. 1994;91(9):3974-3978. (Pubitemid 24139555)
4. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A. 1990;87(15):5978-5982.
5. Haller H, Christel C, Dannenberg L, Thiele P, Lindschau C, Luft FC. Signal transduction of erythropoietin in endothelial cells. Kidney Int. 1996;50(2):481-488. (Pubitemid 26274375)
6. Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood. 1999;93(8):2627-2636. (Pubitemid 29181195)
7. Akimoto T, Kusano E, Inaba T, et al. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int. 2000;58(1):269-282. (Pubitemid 30429872)
8. Ammarguellat F, Llovera M, Kelly PA, Goffin V. Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells. Biochem Biophys Res Commun. 2001;284(4):1031-1038. (Pubitemid 32924752)
9. Gogusev J, Zhu DL, Herembert T, Ammarguellat F, Marche P, Drueke T. Effect of erythropoietin on DNA synthesis, proto-oncogene expression and phospholipase C activity in rat vascular smooth muscle cells. Biochem Biophys Res Commun. 1994;199(2):977-983. (Pubitemid 24181758)
10. Ito C, Kusano E, Furukawa Y, et al. Modulation of the erythropoietin-induced proliferative pathway by cAMP in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2002;283(6):C1715-C1721. (Pubitemid 35340603)
11. Roberts WG, Whalen PM, Soderstrom E, et al. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res. 2005;65(3):957-966. (Pubitemid 40216457)
12. Kumar A, Lindner V. Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol. 1997;17(10):2238-2244. (Pubitemid 28057127)
13. Urao N, Okigaki M, Yamada H, et al. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res. 2006;98(11):1405-1413. (Pubitemid 43948065)
14. Yoshimura A, Misawa H. Physiology and function of the erythropoietin receptor. Curr Opin Hematol. 1998;5(3):171-176.
15. Kundumani-Sridharan V, Wang D, Karpurapu M, et al. Suppression of activation of signal transducer and activator of transcription-5B signaling in the vessel wall reduces balloon injury-induced neointima formation. Am J Pathol. 2007;171(4):1381-1394. (Pubitemid 47582910)
16. Kitamura T, Tojo A, Kuwaki T, et al. Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1. Blood. 1989;73(2):375-380.
17. Monraats PS, Pires NM, Schepers A, et al. Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB J. 2005;19(14):1998- 2004. (Pubitemid 41759745)
18. Reddy MK, Vasir JK, Hegde GV, Joshi SS, Labhasetwar V. Erythropoietin induces excessive neointima formation: a study in a rat carotid artery model of vascular injury. J Cardiovasc Pharmacol Ther. 2007;12(3):237-247. (Pubitemid 47305437)
19. Jubinsky PT, Krijanovski OI, Nathan DG, Tavernier J, Sieff CA. The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood. 1997;90(5):1867-1873. (Pubitemid 27377296)
20. Defilippi P, Rosso A, Dentelli P, et al. {beta}1 Integrin and IL-3R coordinately regulate STAT5 activation and anchorage-dependent proliferation. J Cell Biol. 2005;168(7):1099-1108.